Xcorporeal to Present Posters on Friday, November 7th, at The American Society of Nephrology’s Renal Week 2008
Xcorporeal, Inc. (AMEX:XCR) announced today that Victor Gura M.D., the Company’s Chief Scientific and Medical Officer, will deliver two presentations at The American Society of Nephrology’s (“ASN”) Renal Week, entitled, “The Wearable Artificial Kidney (“WAK”) Removes and Absorbs Uric Acid, Hippuric Acid, Indoxyl Sulphate and Indole Acetic Acid” and “The Push Pull, Double Pulsation Flow in Opposite Phase Improves Ultrafiltration and Convective Transport across the Dialyzer Membrane in the WAK.” Both of these presentations continue to demonstrate the feasibility of a fully wearable hemodialysis device with the potential to effectively remove large molecule toxins.
Dr. Gura will present today at 10.00 a.m. Eastern time. Renal Week is being held at the Pennsylvania Convention Center in Philadelphia, PA from November 4th thru November 9th, 2008.
Additionally, Dr. Gura, along with Dr. Claudio Ronco and Dr. Andrew Davenport, have recently published an article entitled “A Wearable Artificial Kidney, Dream or Reality” in the November 2008 issue of Nature Nephrology. The article may be found at: www.nature.com/ncpneph/journal/v4/n11/full/ncpneph0929.html
Dr. Claudio Ronco is Head of the Department of Nephrology, Dialysis and Transplantation at St. Bortolo Hospital, Vicenza, Italy and a consultant to Xcorporeal. Dr. Davenport is a Consultant and Honorary Senior Lecturer in the University College of London Centre for Nephrology at the Royal Free & University College Medical School, London, UK.
The ASN is organized and operated exclusively for scientific and educational purposes, including enhancing the field of nephrology by advancing the scientific knowledge and clinical practice of that discipline through stimulation of basic and clinical investigation, providing access to new knowledge through the publication of journals and the holding of scientific meetings, advocating for the development of national health policies to improve the quality of care for renal patients, cooperating with other national and international societies and organizations involved in the field of nephrology, and using other means as directed by the Council of the Society.
Xcorporeal, Inc. is a medical device company developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs. The platform leads to three initial products: a Portable Artificial Kidney (PAK) for hospital based Renal Replacement Therapy, the XCR-6 for home hemodialysis, and a Wearable Artificial Kidney (WAK) for continuous ambulatory hemodialysis.
For the hospital market, Xcorporeal is developing a portable, multi-functional renal replacement device that will offer cost-effective therapy for those patients suffering from Acute Renal Failure, which causes a rapid decline in kidney function. In the U.S., the disease affects more than 200,000 patients annually with a mortality rate approaching 50%, according to a study published in the Clinical Journal of American Society of Nephrology in 2006. The Company has completed the development of the product prototype, which is currently undergoing bench testing, and anticipates submitting 510(k) filings, for the device and attendant disposable components, with the Food and Drug Administration (FDA) during 2009.
The Company also plans to commercialize the XCR-6, a home hemodialysis device, for the chronic End Stage Renal Disease (ESRD) market, comprised of patients in whom the kidneys have ceased to function. The Company’s devices are intended to combine the best attributes of currently marketed home hemodialysis machines to offer patients convenient, durable and truly portable treatments at home. The Company believes its devices will provide a cost-effective alternative to current home treatment modalities, due to their ability to offer hemodialysis without the need for large quantities of purified water. The Company has also completed the development of the XCR-6, which is currently undergoing bench testing, and anticipates submitting a 510(k) with the FDA during 2010.
The Company’s WAK is also a device for the chronic treatment of ESRD. The Company has successfully demonstrated a prototype system that weighs less than 5 kg., is battery operated, and can be worn by an ambulating patient while undergoing dialysis. This miniature, wearable device is intended to enable continuous (up to 24 hours x 7 days per week) renal replacement therapy at home. Human studies with the WAK have been described in several scientific peer reviewed publications including Lancet and Kidney International. It was also featured internationally by the general press including the Los Angeles Times, Le Figaro, Corriere de la Sera, Frankfurt Algemeiner.
Additional Company information may be found on the Internet at: www.xcorporeal.com.
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, the risk that our technology may not be effective, uncertainty as to the outcome of arbitration and legal proceedings, intense competition and substantial regulation in the medical device industry; and additional risks factors as discussed in the reports filed by the Company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.